Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2020 942 B
EBIT 2020 -
Net income 2020 82 597 M
Finance 2020 294 B
Yield 2020 1,20%
Sales 2021 951 B
EBIT 2021 -
Net income 2021 84 822 M
Finance 2021 354 B
Yield 2021 1,22%
P/E ratio 2020 48,34
P/E ratio 2021 48,02
EV / Sales2020 4,27x
EV / Sales2021 4,16x
Capitalization 4 316 B
More Financials
Company
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.7%): prescription medicines (93% of net sales) and OTC medicines (7%) primarily for the treatment of thrombotic disorders,... 
Sector
Pharmaceuticals
Calendar
07/29Earnings Release
More about the company
Surperformance© ratings of DAIICHI SANKYO COMPANY, LI
Trading Rating : Investor Rating :
More Ratings
Latest news on DAIICHI SANKYO COMPANY, LI
08:33aDAIICHI SANKYO : VANFLYTA Receives Approval in Japan for the Treatment of Relaps..
AQ
06/17DAIICHI SANKYO : Integral Molecular reaches milestone in I-O target discovery co..
AQ
05/24DAIICHI SANKYO : Announcement Regarding Recent Media Reports
AQ
05/23DAIICHI SANKYO : looking to sell OTC drug unit for about $900 million - Nikkei B..
RE
05/20DAIICHI SANKYO : Announces Update to H5N1 Influenza Vaccine National Project
AQ
05/17DAIICHI SANKYO : FDA advisory panel votes against Daiichi Sankyos quizartinib
AQ
05/16DAIICHI SANKYO : FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiich..
AQ
05/15DAIICHI SANKYO : Precision NanoSystems Signs License Agreement with Daiichi Sank..
AQ
05/15DAIICHI SANKYO : FDA questions credibility of Daiichi data ahead of AdComm
AQ
05/14EXELIXIS' : Collaborator Daiichi Sankyo Launches MINNEBRO Tablets in Japan
AQ
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LI
More recommendations
Sector news : Pharmaceuticals - NEC
02:24pPFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
02:22pGLAXOSMITHKLINE : GSK kicks off sale of $1.2 billion consumer health drugs - sou..
RE
12:27pCEOs of some U.S. firms to meet Chinese Premier Li this week - Bloomberg
RE
10:47aSANOFI : plans 466 job cuts as part of R&D reshuffle
RE
09:31aGLOBAL MARKETS LIVE : Viacom, Apple, Siemens, Boeing…
More sector news : Pharmaceuticals - NEC
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
DAIICHI SANKYO COMPANY, LIMITED Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 6 472  JPY
Spread / Average Target 6,3%
EPS Revisions
Managers
NameTitle
Joji Nakayama Chairman & CEO
Sunao Manabe President, COO & Representative Director
Toshiaki Sai CFO, Representative Director & Vice President
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Katsumi Fujimoto Director & Senior Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED78.77%35 780
JOHNSON & JOHNSON8.05%348 981
PFIZER-1.76%233 072
ROCHE HOLDING LTD.14.56%227 848
NOVARTIS23.07%220 893
MERCK AND COMPANY9.02%206 641